Document is current

Article History

Received: 18 March 2024

Accepted: 25 October 2024

First Online: 11 November 2024

Competing interests

: M.D. is an employee of and holds stock options at Dracen Pharmaceuticals Inc. R.W. is an employee of, receives consulting fees from, and holds stocks and stock options at Dracen Pharmaceuticals Inc. S.W.-R. has received speaker honoraria from AstraZeneca and Invitae; and received support for attending meetings and travel from AstraZeneca and Novartis. S.M.-B. has received speaker honoraria from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Merck, Merck Sharp & Dohme, Molecular Health, Novartis, Pfizer, QuIP, and DLS; and participates on advisory boards for AstraZeneca, Qiagen, and Roche. J.W. received research funds from Dracen Pharmaceuticals Inc., received research support (to institution) from Bristol-Myers Squibb, Janssen Pharmaceuticals, Novartis, Pfizer, and Biontech; and received consulting fees from Amgen, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Boehringer Ingelheim, Chugai Europe, Daiichi-Sankyo, Ignyta, Jannsen, Eli Lilly, Loxo, Merck, Mirati, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Seattle Genetics, Taked, and Turning Point. R.B. is funded by the German Cancer Aid in the program “Excellence Center for Oncology-CIO ABCD, Center for Molecular Medicine; has received consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Illumina, Janssen, Eli Lilly, Merck-Serono, Merck Sharp & Dohme, Novartis, Qiagen, Pfizer, Roche, Sanofi, Targos MP Inc.; received lecture and presentation honoraries from AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Illumina, Janssen, Eli Lilly, Merck-Serono, Merck Sharp & Dohme, Novartis, Qiagen, Pfizer, Roche, and Targos MP Inc.; is a member of the board of trustees of the German Cancer Aid; chairs the board of trustees for the Vladimir Totovic Foundation of the German Division Internation Academy of Pathology; and is co-owner of Timer Therapeutics (Germany) and Gnothis Inc. (Sweden). L.C. is a paid consultant of Dracen Pharmaceuticals. M.S. received research funds from Dracen Pharmaceutical Inc.; has received grants or holds contracts with Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Novartis, Pfizer, Roche, Sanofi-Aventis, Siemens Healthineers, Takeda, and Bristol-Myers Squibb; received support for attending meetings or travel from Janssen and Pfizer; and has a leadership or fiduciary role at the European Society for Medical Oncology and European Organization for Research and Treatment of Cancer. A.M.H. received research funds (to institution) from Dracen Pharmaceuticals Inc. The remaining authors declare no conflict of interest.